For instance, recently OSU-2S, an analogue of FTY720, has been developed for the treatment of acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL) through the inhibition of SET, where it results in the interference of the c-Myc/p21 and SHP1 [89, 90]. This evidence concerns the gene MYC and B-cell chronic lymphocytic leukemia.